Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature (ELEGANCE)
Sponsor: Boston Scientific Corporation
This observational or N/A phase trial investigates Peripheral Vascular Diseases and is currently actively recruiting participants. Boston Scientific Corporation leads this study, which shows 55 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)A global prospective, non-randomized, open-label, multi-center Registry to collect Real-World Data, including health economic data, to support the use of commercially available drug-eluting BSC devices for the treatment of lesions located in the peripheral vasculature.
A global prospective, non-randomized, open-label, multi-center Registry to collect Real-World Data, including health economic data, to support the use of commercially available drug-eluting BSC devices for the treatment of lesions located in the peripheral vasculature.
Status Flow
Change History
55 versions recorded-
Apr 21, 2026 — Present [daily]
Recruiting
-
Mar 2026 — Apr 2026 [monthly]
Recruiting
-
Feb 2026 — Mar 2026 [monthly]
Recruiting
-
Jan 2026 — Feb 2026 [monthly]
Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Recruiting
▶ Show 50 earlier versions
-
Nov 2025 — Dec 2025 [monthly]
Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Recruiting
-
Aug 2025 — Sep 2025 [monthly]
Recruiting
-
Jul 2025 — Aug 2025 [monthly]
Recruiting
-
Jun 2025 — Jul 2025 [monthly]
Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting
-
Apr 2025 — May 2025 [monthly]
Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
-
Jan 2025 — Feb 2025 [monthly]
Recruiting
-
Dec 2024 — Jan 2025 [monthly]
Recruiting
-
Nov 2024 — Dec 2024 [monthly]
Recruiting
-
Oct 2024 — Nov 2024 [monthly]
Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
-
May 2024 — Jun 2024 [monthly]
Recruiting
-
Apr 2024 — May 2024 [monthly]
Recruiting
-
Mar 2024 — Apr 2024 [monthly]
Recruiting
-
Feb 2024 — Mar 2024 [monthly]
Recruiting
-
Jan 2024 — Feb 2024 [monthly]
Recruiting
-
Dec 2023 — Jan 2024 [monthly]
Recruiting
-
Nov 2023 — Dec 2023 [monthly]
Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Recruiting
-
Aug 2023 — Sep 2023 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting
-
May 2023 — Jun 2023 [monthly]
Recruiting
-
Apr 2023 — May 2023 [monthly]
Recruiting
-
Mar 2023 — Apr 2023 [monthly]
Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Recruiting
-
Oct 2022 — Nov 2022 [monthly]
Recruiting
-
Sep 2022 — Oct 2022 [monthly]
Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting
-
Jun 2022 — Jul 2022 [monthly]
Recruiting
-
May 2022 — Jun 2022 [monthly]
Recruiting
-
Feb 2022 — May 2022 [monthly]
Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Recruiting
-
Oct 2021 — Nov 2021 [monthly]
Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting
-
Jun 2021 — Sep 2021 [monthly]
Recruiting
-
May 2021 — Jun 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Mar 2021 — May 2021 [monthly]
Not Yet Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Contact Information
- Boston Scientific Corporation
For direct contact, visit the study record on ClinicalTrials.gov .